ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,205.54
0.34%
Dow Jones
39,306.16
0.64%
US Dollar vs MXN
16.8571
-0.37%
Brent Oil
83.535
-0.03%
Bitcoin
62,019.55
1.36%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Cara Therapeutics Inc (CARA)

  7. Cara Therapeutics Inc (CARA) Noticias

CARA

Cara Therapeutics (CARA)

Cara Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CARA
FechaHoraFuenteTítuloSímboloCompañía
06/05/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CARACara Therapeutics Inc
06/05/202406:00GlobeNewswire Inc.Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024NASDAQ:CARACara Therapeutics Inc
02/04/202406:00GlobeNewswire Inc.Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:CARACara Therapeutics Inc
07/03/202406:00GlobeNewswire Inc.Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024NASDAQ:CARACara Therapeutics Inc
06/03/202415:45Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CARACara Therapeutics Inc
04/03/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARACara Therapeutics Inc
04/03/202415:01GlobeNewswire Inc.Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
13/02/202417:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CARACara Therapeutics Inc
12/02/202415:01GlobeNewswire Inc.Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024NASDAQ:CARACara Therapeutics Inc
22/01/202406:00GlobeNewswire Inc.Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026NASDAQ:CARACara Therapeutics Inc
18/12/202306:00GlobeNewswire Inc.Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic DermatitisNASDAQ:CARACara Therapeutics Inc
13/11/202315:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CARACara Therapeutics Inc
13/11/202315:01GlobeNewswire Inc.Cara Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
02/11/202306:00GlobeNewswire Inc.Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare RoyaltyNASDAQ:CARACara Therapeutics Inc
23/10/202306:00GlobeNewswire Inc.Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023NASDAQ:CARACara Therapeutics Inc
25/09/202306:00GlobeNewswire Inc.Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis PatientsNASDAQ:CARACara Therapeutics Inc
05/09/202306:00GlobeNewswire Inc.Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CARACara Therapeutics Inc
07/08/202315:01GlobeNewswire Inc.Cara Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
04/08/202316:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CARACara Therapeutics Inc
03/08/202306:00GlobeNewswire Inc.Cara Therapeutics Appoints Helen M. Boudreau to Board of DirectorsNASDAQ:CARACara Therapeutics Inc
02/08/202306:00GlobeNewswire Inc.Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceNASDAQ:CARACara Therapeutics Inc
24/07/202306:00GlobeNewswire Inc.Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023NASDAQ:CARACara Therapeutics Inc
27/06/202315:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CARACara Therapeutics Inc
02/06/202317:46PR Newswire (US)Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600NASDAQ:CARACara Therapeutics Inc
02/06/202315:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CARACara Therapeutics Inc
01/06/202306:00GlobeNewswire Inc.Cara Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:CARACara Therapeutics Inc
18/05/202301:00PR Newswire (US)Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusNASDAQ:CARACara Therapeutics Inc
18/05/202301:00GlobeNewswire Inc.Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusNASDAQ:CARACara Therapeutics Inc
15/05/202315:01GlobeNewswire Inc.Cara Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:CARACara Therapeutics Inc
01/05/202306:00GlobeNewswire Inc.Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023NASDAQ:CARACara Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CARA

Su Consulta Reciente

COIN
SOLUSD
Solana
USOTC
RHHBY
Roche (QX)
NYSE
CVX
Chevron
USOTC
ADDYY
Adidas (QX)
AMEX
XLV
Health Care Select Sector
AMEX
SPY
SPDR S&P 500
USI
USTECH100
US Tech 100
FX
EURUSD
Euro vs US Dollar
COIN
ETHUSD
Ethereum
CCOM
SILVER
SILVER
FX
EURMXN
Euro vs MXN
NASDAQ
NVDA
NVIDIA
NYSE
JPM
JP Morgan Chase
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
AXP
American Express
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados